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E normous advances in melanoma epidemiology, diagnosis, andtreatment have occurred in the past 60 years. Before the 1960s,
60% of patients diagnosed with melanoma died, whereas today only
11% have a fatal outcome.1 These advances have been the result of
greater understanding of risk factors, improvement in early detec-
tion, and a worldwide increase in education and public awareness,
far more so than any advances in treatment. Nonetheless, significant
treatment advances have taken place over this time as well. A large
number of important scientific and clinical contributions to mela-
noma have been published in Cancer in the 60 years of its exis-
tence. Many are highlighted in this review, along with other
pertinent references from the rest of the medical literature that
built on, substantiated, or foreshadowed these key contributions.
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EPIDEMIOLOGY, DIAGNOSIS, SCREENING, AND
PROGNOSIS
The detailed clinicopathologic criteria for melanoma
diagnosis and prognosis, published in Cancer by Drs
Allen and Spitz in 1953, provided a foundation on
which our current melanoma knowledge is based.2
They noted the adverse prognostic impact of ulcera-
tion or an elevated mitotic rate. Indeed, ulceration
became an established independent prognostic factor
in primary melanoma in the revised 2001 American
Joint Commission on Cancer staging system.3 The
prognostic relevance of mitotic rate has been con-
firmed,4 and subsequently extended to predicting
sentinel lymph node status.5,6 Another early observa-
tion of Drs. Allen and Spitz, that of a better survival
for women with melanoma,2 has stood the test of
time.7 During the period from 1969 to 1999, overall
melanoma mortality increased approximately 50%,
from 2 deaths per 100,000 to 3 deaths per 100,000,
but the increase was disproportionately greater in
men aged 65 years (an increase of 157%, 3-fold
greater than the rate for women of the same age).8
Furthermore, thick tumors of 4 mm have increased
significantly only in men aged 60 years,9 and older
men are more often diagnosed with the nodular sub-
type of melanoma.10 Although several hypotheses
have been advanced, including sex differences in
skin awareness, none have yet fully explained why
men have a disproportionate risk of developing thick
melanomas.
Many others contributed critical observations to
melanoma diagnosis, risk factors, and early detec-
tion. Drs. Mihm and Fitzpatrick emphasized early on
that the most important tool for the early detection
of melanoma was a careful complete skin examina-
tion from scalp to toe.11 Moreover, greater than 25
years ago, members of the Melanoma Clinical Coop-
erative Group reported on the clinical characteristics
of early cutaneous melanoma: increase in pigmented
lesion size and presence of color change.12 These
features were subsequently incorporated in the
ABCD mnemonic, and more recently in the revised
ABCDE criteria for early melanoma diagnosis.13 The
addition of the E criterion, standing for ‘‘evolution,’’
has been an important addition to melanoma early
detection. Among others items, it captures the symp-
tom of itching that appears to be relevant for the
detection of a subset of thin melanomas,14 and is
commonly reported among patients presenting with
invasive melanomas.15
Although today risk factors for melanoma are
well known, it is worth noting that several were high-
lighted by scientific contributions in Cancer. The im-
portance of regular follow-up of patients with
dysplastic nevi16 and the occurrence of dysplasia in
nonfamilial melanoma17 were both first described in
Cancer. Grob et al confirmed that the total number
of melanocytic nevi was also a major indicator of
risk of nonfamilial melanoma.18 Recognition of the
importance of following patients with basal cell or
squamous cell carcinoma emphasized how these
patients were at risk for melanoma and described
the magnitude of the risk.19 Goggins and Tsao
showed that melanoma survivors’ risk of a second
melanoma was highest in the first few months, but
that this risk remained substantially higher than the
risk of a first melanoma in the general population
over a >20-year period of observation.20 More
recently, the report of an increased incidence of mel-
anoma in renal transplant recipients has brought to
light this group of at-risk patients who now live lon-
ger, more active lives.21
Certain groups, such as children and pregnant
women, developing melanoma were also discussed
early on in Cancer publications. Among the early
reports of melanoma in children, many were in
Cancer.2,22-25 Barnhill et al called attention to the chal-
lenges involved in discriminating childhood melanoma
from Spitz nevi and provided criteria defining atypical
Spitz tumors.26 Su et al examined the role of sentinel
lymph node biopsy in atypical Spitz tumors.27 More
recently, Livestro et al conducted a case–control study
comparing outcomes for childhood and adult melano-
mas, showing an equal or better outcome for children
despite a higher rate of sentinel lymph node positiv-
ity.28 Several reports of melanoma in pregnancy were
published early in the history of Cancer.29-31 In 1 popu-
lation–based cancer registry of melanoma in preg-
nancy, the data suggested that melanoma during
pregnancy carried a poor prognosis, although once the
diagnosis was made, the course was not worse than
expected for the stage.32 Another study suggested that
having a subsequent pregnancy had no effects on re-
currence rate or survival.33 More recently, a study from
Germany highlighted that pregnancy did not appear to
have an adverse long-term effect on survival in patients
with clinically localized melanoma.34 Currently, there is
broad agreement that prognosis for women with mela-
noma during pregnancy, just as for nonpregnant
women and for men, is primarily dependent on tumor
thickness and ulceration.
The appropriate diagnosis of cutaneous mela-
noma and the need for prevention and early detec-
tion were emphasized by the many contributions of
Drs. Sober and Kopf.35-38 The early diagnosis of mel-
anoma has allowed the US and Australia to improve
their 5-year survival rates (currently >90%).1 There
remains much work to be done, because early detec-
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tion and screening methods have remained under-
used in many parts of the world, in particular in sev-
eral Eastern European countries and Northern
Ireland, in which 5-year survival rates are notably
lower (53%-60%).39
It is worth noting that Koh et al were the first to
bring an evaluation component into our approach to
melanoma screening.40 They demonstrated that the
sensitivity of the visual examination by a dermatolo-
gist was 89% to 97%, with a positive predictive value
of 35% to 75%, confirming its appropriateness as a
cancer screening tool. McDonald subsequently sum-
marized US melanoma screening efforts.41 In the
same context, Rhodes comprehensively emphasized
public and professional education for the primary
and secondary prevention of melanoma, and recom-
mended personal responsibility in this process to
ultimately reduce morbidity and mortality.42 Koh
et al subsequently provided a framework in which to
evaluate screening of melanoma.43 Geller et al took
this challenge and carefully evaluated the American
Academy of Dermatology screening program.44 The
authors showed that middle-aged and older men
(aged 50 years) accounted for only 25% of screen-
ees, but comprised 44% of those with a confirmed
diagnosis of melanoma. They suggested that mass
screening for melanoma could be improved by out-
reach to middle-aged and older men. Researchers in
Australia planned and began a randomized con-
trolled trial of a community-based intervention of
screening for melanoma. Although the lack of gov-
ernmental funding did not allow completion of the
study, data from 18 of 44 communities enrolled in
Queensland demonstrated that the intervention pro-
gram had successfully motivated men aged >50
years to undergo screening for skin cancer, resulting
in the highest yield of skin cancer within this sub-
group.45 Data regarding melanoma mortality have
consistently shown that older men have higher dis-
ease-specific mortality. These recent studies confirm
the relevance of targeting our screening efforts to
older men.46
Ascertaining whether a patient has a family his-
tory of melanoma is an important aspect of history
taking, but also provides opportunities for patient
and family education. Geller et al demonstrated in a
randomized control trial that siblings of melanoma
patients who had received an intervention were
more likely to examine all their moles 12 months
later, including the ones on their backs.47 Skin self-
examination has a role in reducing melanoma mor-
tality; as Berwick et al demonstrated, it could poten-
tially reduce mortality related to melanoma by
63%.48 Indeed, in a study in New York, skin self-
examination was found to be a key predictor of pre-
sentation with a melanoma <1 mm in thickness.49
Several groups have reported on multiple primary
melanomas (MPM).50-52 Blackwood et al examined
the frequency of family history of melanoma in cases
with MPM and found close to half had a positive
family history.53 Families of MPM patients also had a
high incidence of dysplastic nevi and basal cell carci-
noma, suggesting that they would benefit from
screening, skin self-examination, and regular skin
surveillance. Thus, the families of MPM patients
should be screened as well.
Although we generally think of the principal mel-
anoma subtypes as superficial spreading, nodular,
lentigo maligna, and acral lentiginous melanoma,
one should not forget the desmoplastic type. To our
knowledge, the first ever description of desmoplastic
melanoma was in Cancer, by Conley et al in 1971: ‘‘a
rare variant of spindle cell melanoma.’’54 Since 1971,
several works, including many published in Cancer,
have contributed to our knowledge of desmoplastic
melanoma, including the higher local recurrence
associated with the propensity for neurotropism, the
lower incidence of lymph node metastases, especially
in the pure histological variant, and the possible role
of radiation.55-61 Desmoplastic melanomas are more
common on the head and neck, may look innocuous,
and are frequently amelanotic; a high index of suspi-
cion is needed to allow timely biopsy.
Throughout the history of Cancer, articles have
highlighted the metastatic potential of thin melano-
mas.62-64 In particular, the presence of regression has
attracted attention and provoked debate as a potential
factor affecting prognosis.62,65 The presence of regres-
sion has not been consistently shown to impact prog-
nosis of thin melanomas, although those thin
melanomas with extensive regression appear to be
over-represented among patients developing metasta-
ses.46,66 The jury is still out, but increasingly data
show that regression does not adversely impact either
prognosis or the likelihood of finding a positive senti-
nel lymph node.6,67,68 Although the debate continues
as to whether either regression or Clark level should
be used to select patients with melanomas thinner
than 1 mm for sentinel lymph node biopsy,68,69 data
continue to accumulate supporting a potential role
for mitotic rate in this decision-making process.5,70
A provocative observation first made in Cancer
was that there appeared to be no correlation between
time to diagnosis and tumor thickness.71 The authors
observed highly variable rates of growth among differ-
ent primary melanomas and speculated regarding
heterogeneity in primary melanomas’ inherent biol-
ogy. Twenty-five years later we have overwhelming
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evidence for the genetic heterogeneity of the entity
we call cutaneous melanoma.72-74 Several pathways
may result in melanoma development, and under-
standing this heterogeneity may allow us to improve
on our treatment of advanced disease. In this regard,
the changing epidemiology of melanoma over the last
decades seen in data from certain countries raises
several questions. In Southern Sweden, a population-
based study of histopathologically reviewed melano-
mas from 1965, 1975, and 1985 showed no significant
decrease in mean tumor thickness over the time pe-
riod, although survival had improved.75 A recent
update from the same group showed that none of the
known prognostic factors such as age, sex, and
ulceration explained the increased survival of mela-
noma patients for that period.76 Similarly, Germany
reported an improvement in overall survival of
patients for the period 1990 to 2001 as compared with
1976 to 1989 that could not be entirely attributed to
early diagnosis and more favorable primary tumors.77
Although in an earlier analysis the median tumor
thickness had decreased from 1.81 mm in 1976 to
0.53 mm in 2000,78 when a multivariate analysis was
performed, the more recent time period was an inde-
pendent factor portending an improved prognosis.77
One can only postulate as to the possible factors
other than early detection that would contribute to
this changing epidemiology. Have changing patterns
of sun exposure altered the biology of melanoma, or
the distribution of hitherto unappreciated biologic
subtypes, impacting overall survival? Are there envir-
onmental factors other than sun exposure that have
been altered? The prevalence of smoking has
decreased in North America and in Europe. Smoking
is known to influence melanoma prognosis,79 and 1
study also suggests an impact on melanoma risk.80
The contributing role of vitamin D, occupational
exposures, redox-active metals, and smoking to mela-
noma incidence and survival are research questions
that will need to be answered. Of all these possible
factors, the role of vitamin D—and the suggestion
that sun exposure is actually desirable from a health
perspective—has received the most public attention.
Melanoma clinicians have an obligation to under-
stand the essential elements of the debate,81 and rec-
ognize that even if vitamin D is important in some as
yet undefined way in cancer incidence or outcome,
oral supplementation rather than increasing solar ex-
posure is the appropriate response.82
SURGICAL TREATMENT OF MELANOMA
Compared with most solid tumors, for which the
past several decades have seen dramatic shifts from
surgical to multidisciplinary management, the treat-
ment of melanoma therapy has remained centered
on resection. Surgery provides the best hope for
long-term survival, not only for early-stage disease,
but also for patients with regional and potentially
distant disease. The nature of that surgery, however,
has changed dramatically, resulting in significantly
less morbidity, improved staging and identification of
micrometastases, and enhanced survival.
One of the most dramatic changes in melanoma
surgery over the past 60 years has been the extent of
the primary excision for melanoma. On the basis of
observations of local recurrence rates as high as 60%
with surgeries designed solely to excise the visible
primary tumor without a defined surrounding mar-
gin of normal tissue, the radical wide excision has
been the cornerstone of melanoma surgery since it
was first described by William Norris in 1857.83 Very
quickly, radical excisions of 3 to 5 cm beyond the
primary became the standard of care. The morbidity
of these surgeries was significant, with little data to
support whether survival was improved. This led to
the design and implementation of several rando-
mized trials to answer whether such wide margins
(3, 4, or 5 cm) were necessary, or whether more nar-
row (1 or 2 cm) margins were adequate.84-86 Two of
these important studies were published in Cancer.
Cohn-Cedermark et al reported the results of the
Swedish Melanoma Study Group trial, which evalu-
ated 989 patients with primary melanomas between
0.8 and 2.0 mm thick.87 Patients were randomly allo-
cated to excision with a 2-cm or a 5-cm margin.
There were no statistically significant differences in
local recurrence rates or survival between the 2
arms. Similar results were published by Khayat et al,
who randomly assigned 326 patients with melano-
mas 2 mm in thickness to 2-cm versus 5-cm mar-
gins.88 This trial also demonstrated no differences in
local recurrence or survival. Cumulatively, the results
of all these trials established that 1-cm margins of
excision were adequate for thin (1 mm) melano-
mas, and that margins of excision greater than 2 cm
beyond the primary melanoma were not necessary
for most melanomas >1 mm in thickness.
Beyond the changing surgical margins, the most
dramatic change in the surgical management of mel-
anoma has clearly been the management of the clini-
cally normal regional lymph node basin. Only
approximately 10% of patients have clinical evidence
of lymph node metastases at the time they initially
present with melanoma (ie, palpably abnormal
lymph nodes), but the approach to these patients
remains basically unchanged. After confirming the
presence of melanoma within the palpable lymph
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nodes by fine-needle aspiration cytology (and not
excisional biopsy unless the fine- needle aspiration is
inconclusive), these patients should be staged to rule
out the presence of asymptomatic distant disease. At
a minimum, this should include a thorough history
and physical examination, chest radiograph, and se-
rum lactate dehydrogenase level, with any abnormal-
ities prompting a more thorough search for
metastases. Several investigators have shown that the
use of computed tomography (CT) scans, (18F)-
fluoro-deoxyglucose positron emission tomography
(PET), or fused PET-CT scans in this setting will
upstage a significant percentage of patients to stage
IV, which alters the treatment options. Tyler et al,
publishing in Cancer, reported that PET scans of
patients with stage III disease will change the man-
agement in 15% of cases, helping to establish the
role of PET scanning in this setting.89 For patients
without evidence of distant metastases, radical
lymphadenectomy (complete lymph node dissection)
along with the primary melanoma excision is poten-
tially curative, with 5-year survival rates ranging from
25% to 50% depending on the extent of lymph node
involvement. Complete lymph node dissection is
defined, in the case of palpable axillary metastases,
as removal of level I, II, and III lymph nodes. For
patients with cervical lymph node metastases, the
gold standard has been radical neck dissection to
remove the lymph nodes in levels I to V, although
more recently several studies have demonstrated no
difference in recurrence or survival with modified
radical neck dissections. A more controversial ques-
tion has been the extent of the inguinal dissection
when the patient presents with palpable inguinal ad-
enopathy. Some surgeons advocate routine excision
of both the inguinal and the pelvic lymph nodes (so-
called ‘‘superficial and deep groin dissection’’).
Others have advocated a more selective approach to
the pelvic lymph nodes. Clearly, radiologic evidence
of involvement of the pelvic lymph nodes on CT or
PET is an indication for including the pelvic dissec-
tion. Another criteria that has been advocated has
been the presence of disease in Cloquet lymph node,
the lymph node situated between the inguinal and
pelvic basins. However, Shen et al demonstrated that
the absence of disease in Cloquet lymph node does
not accurately predict the absence of involvement of
the iliac lymph nodes.90 Additional research is
needed to understand the relative value of the deep
dissection as well as its additional morbidity, for
patients presenting with palpable lymph nodes.
However, a pessimistic attitude that pelvic lymph
node involvement is synonymous with incurable dis-
ease cannot be justified.91
The area in which the surgical management of
melanoma has changed most dramatically is in the
approach to patients who present with clinically neg-
ative regional lymph nodes. It is recognized that
20% of patients with melanomas 1 mm in thick-
ness who present with clinically negative regional
lymph nodes will eventually manifest clinically evi-
dent lymph node metastases. Historically, many sur-
geons advocated elective lymph node dissection
(ELND), with the idea that early clearance of tumor
deposits in the regional lymph node basin could pre-
vent subsequent dissemination. However, given the
significant morbidity of ELND, there was great inter-
est in determining whether the procedure impacted
overall survival. Four prospective trials evaluated the
benefit of ELND for patients with melanoma, includ-
ing 1 by Veronesi et al in Cancer.92-95 All 4 trials
failed to demonstrate a survival benefit for ELND,
radically changing the paradigm for management of
melanoma away from routine ELND to lymph node
observation. However, the management paradigm
would change even more dramatically with the intro-
duction of lymphatic mapping and sentinel lymph
node biopsy.
The landmark report by Morton et al in 1992 on
the technique of lymphatic mapping and sentinel
lymph node biopsy in the management of melanoma
revolutionized the staging and management of mela-
noma.96 Sentinel lymph node biopsy is a minimally
invasive procedure for identifying patients with
occult lymph node metastases. It is best performed
at the time of wide excision of the primary, although
it may still be performed in selected patients who
already had a wide excision, as demonstrated by
Gannon et al in Cancer.97 The hypothesis underpinning
the technique is that melanoma metastases within a
lymph node basin evolve in an orderly fashion, with
metastasis to the sentinel lymph node as the first step
in the process. Identification and removal of the senti-
nel lymph node accurately stages that lymph node
basin and, in turn, identifies those patients who would
not be likely to benefit from a full lymph node dissec-
tion. The accuracy of the sentinel lymph node in
reflecting the pathologic status of the entire regional
basin has been confirmed in multiple studies.98,99
In addition to preventing unnecessary lymphade-
nectomies, sentinel lymph node biopsy also allows
for more accurate staging than elective lymph node
dissection. With significantly fewer lymph nodes to
examine, the pathologist can serially step-section the
lymph node (as opposed to simply bisecting it) for
both routine hematoxylin and eosin staining and im-
munohistochemical staining for melanoma markers
such as S-100, Melan-A, and HMB-45. The benefit of
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this approach was clearly demonstrated by 2 studies
in the pages of Cancer. Yu et al reported that examin-
ing sentinel lymph nodes with multiple sections and
immunohistochemical staining detected metastases
in 12% of cases that would otherwise have been
reported as negative.100 Abrahamsen et al also
demonstrated that serial sectioning with immunohis-
tochemical staining increased the detection of micro-
metastases.101 These articles helped establish step-
sectioning and immunohistochemical staining as the
standard of care in the pathologic evaluation of the
melanoma sentinel lymph node.
With sentinel lymph node biopsy established as
the standard staging procedure for clinically negative
regional lymph nodes, many investigators have
sought to refine which patients should undergo the
procedure. Sentinel lymph node biopsy is currently
recommended routinely for all otherwise healthy
patients with melanomas 1.0 mm thick, and used
selectively by most surgeons for patients with thin
melanomas (<1.0 mm). Two publications in Cancer
demonstrated how factors beyond Breslow depth
may help select patients with thin melanomas who
should undergo sentinel lymph node biopsy, and
ultimately perhaps define subsets of patients with
melanomas 1.0 mm who may not need the proce-
dure by virtue of a very low risk of occult lymph
node metastasis. Kruper et al, using classification
tree analysis, reported that variables such as vertical
growth phase, lymphocytic infiltration, and mitotic
rate could be used to identify patients at high and
low risk for harboring sentinel lymph node metasta-
ses.102 Paek et al provided additional evidence that
patient age, mitotic rate, and primary tumor location
could be used in addition to Breslow depth to deter-
mine the risk of a positive SLN.6 With validation and
additional data, these reports may ultimately lead to
different selection criteria for SLN biopsy.
One of the most important questions regarding
sentinel lymph node biopsy is the impact that the
early removal of microscopic regional disease has on
overall survival. Interim results of the Multicenter
Selective Lymphadenectomy Trial I, which rando-
mized patients to wide excision alone or wide exci-
sion plus sentinel lymph node biopsy, with complete
lymph node dissection for any patients with a posi-
tive lymph node, provided some crucial information.
The 5-year survival for patients who had a complete
lymph node dissection on the sentinel lymph node
biopsy arm (including patients with positive sentinel
lymph nodes as well as those patients who had a
false-negative sentinel lymph node biopsy) was sig-
nificantly better than for those patients undergoing
complete lymph node dissection for a recurrence on
the wide excision arm (66.2% vs 54.2%%; hazards ra-
tio, 0.62 [P<.02]).103 An unresolved question is how
much the subsequent completion dissection benefits
the patient over and above the sentinel lymph node
biopsy, because in many cases the sentinel lymph
node may be the only lymph node found histologi-
cally to contain disease. This has prompted several
authors to try to identify patients at low risk of har-
boring additional microscopically evident disease in
the nonsentinel lymph nodes.104,105 The experience
of Wagner et al, as published in Cancer, has been
representative; most investigators have had difficulty
reliably predicting which patients may safely avoid a
lymph node dissection.106 These reports have cemen-
ted the completion lymph node dissection as the
standard of care when a patient has a positive senti-
nel lymph node, at least for now. This question is
being prospectively addressed in the Multicenter
Selective Lymphadenectomy Trial II, which rando-
mizes patients with a positive sentinel lymph node
to completion dissection or observation with serial
ultrasonography of the regional basin.
In addition to lymph node dissections, the surgi-
cal management of regional disease includes the
control of in-transit and satellite metastases. In-tran-
sit and satellite metastases develop in 5% to 8% of
patients with melanomas >1.5 mm in thickness.107
Initially, satellite lesions were defined as skin invol-
vement within 2 cm of the primary tumor, whereas
in-transit metastases were >2 cm from the primary
tumor. Historically, these lesions were considered
and treated separately. However, Singletary et al
demonstrated in Cancer that classifying these lesions
on the basis of distance from the primary tumor had
no prognostic significance.108 The current American
Joint Committee on Cancer staging system for mela-
noma merges satellite metastases and in-transit dis-
ease into a single staging entity within stage III
disease.3,109
The management of in-transit disease remains
extremely challenging. Although surgery may be rea-
sonable when the number of lesions is small, this
occurs in only the minority of cases. When the dis-
ease is confined to an extremity, however, isolated
limb perfusion consisting of regional administration
of high-dose chemotherapy, usually melphalan, has
been shown to be extremely useful in controlling dis-
ease. Minor et al, in Cancer, demonstrated how iso-
lated limb perfusion allows for doses up to 15 to 25
times higher than could be obtained with systemic
therapy,110 and several articles published in Cancer
have documented high complete and partial
response rates.110-112 The duration of response to iso-
lated limb perfusion is typically 9 to 12 months, but
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a subgroup (approximately 20% to 25% of the total
patient population) can have sustained complete
responses. Toxicities range from mild erythema and
edema to extensive epidermolysis and functional
impairment, and can rarely result in the need for
amputation. For patients whose disease is still lim-
ited to the extremity on recurrence, reperfusion may
be possible.113,114
A newer approach to in-transit disease is that of
isolated limb infusion (ILI), a less invasive and less
toxic approach.115 Access is gained to the circulation
of the affected limb by percutaneous radiologic
techniques, and a tourniquet is inflated around
the proximal limb. The chemotherapeutic agent is
then infused into the isolated limb, albeit at lower
doses than those used with isolated limb perfusion
(ILP), because there will be some systemic leakage.
In 1 series using melphalan and dactinomycin,
the overall response in limbs treated by ILI was
85%, with a complete response of 41% and a partial
response of 44%, and the median duration of
response was 16 months, results that compare
favorably with the more invasive and complex
technique of ILP.116 Currently, ILI is being further
evaluated in phase 2 trials.
Finally, a role for surgery in the treatment of
stage IV melanoma has emerged over the last dec-
ade. For most solid tumors, the development of dis-
tant metastases heralds the end of involvement by
the surgeon. For melanoma, however, there is docu-
mented long-term survival among patients after
complete resection of metastatic lesions.117 Careful
patient selection is required, taking into account the
stage of the original melanoma, the disease-free
interval, the number and site of the metastases, the
patient’s current health status, the feasibility of com-
plete resection, and the morbidity of the planned
operation, and most patients will not be candidates.
The potential of surgical resection in stage IV disease
and the importance of proper patient selection was
nicely illustrated by Meyer et al in a retrospective
review of 444 patients with stage IV melanoma.118
CYTOTOXIC CHEMOTHERAPY IN MELANOMA
Despite many studies, the results of cytotoxic chem-
otherapy for metastatic melanoma have remained
disappointing. Median survival for newly diagnosed
metastatic melanoma patients remains under 1 year
even with the newest combination therapies. A com-
prehensive and critical review of the melanoma
chemotherapy literature over the last 40 years has
been published recently in Cancer,119 but many of
the original studies appeared there as well.
The very first trial of dacarbazine (DTIC) in mel-
anoma was reported in Cancer in 1971.120 In this trial
at the ‘‘University of Sydney Professorial Surgical
Unit,’’ DTIC was given at a dose of 4.5 mg/kg daily
for 10 days. Four of 20 patients had an objective
response after a single cycle of treatment, and the
authors observed that ‘‘intravenous DTIC therapy
was easy to administer and not distressing to the
patient.’’ Many different schedules and combinations
of DTIC in melanoma have been explored over the
last 36 years, and the drug was ultimately approved
by the US Food and Drug Administration for use in
melanoma. A prescient review by Luce appeared the
next year in Cancer, summarizing the response rates
to chemotherapy: 5%-28% for single agents and up
to 50% for the combination of dactinomycin and vin-
cristine.121 Luce also attempted to correlate clinical
response with responses observed in murine model
systems, and found no correlation for 11 chemother-
apy drugs then under investigation. This endeavor
continues to beguile investigators: predicting
response in human cancer remains very difficult to
this day.
A serious toxicity of DTIC, hepatic veno-occlu-
sive disease, was first reported in Cancer.122 A much
more common toxicity of DTIC, nausea and vomit-
ing, is today much less problematic thanks to the
common use of highly effective 5HT-3 receptor
antagonists such as ondansetron and granisetron.
Indeed, use of ondansetron to prevent DTIC-induced
nausea was first reported in Cancer in a trial by
Legha et al.123
Multiple DTIC-containing combinations have
been tested over the years, many demonstrating
higher response rates than DTIC alone. Three DTIC-
containing regimens were compared by Wittes et al
in 1978, showing no marked superiority for any regi-
men in response rates or survival.124 This was just 1
harbinger of many failures of combination chemo-
therapy to demonstrate a clear advantage over DTIC
alone. The widely used 4-drug ‘‘Dartmouth regimen’’
(DTIC, cisplatin, carmustine, and tamoxifen)125 was
prospectively compared with DTIC alone in a coop-
erative group study. Although the combination regi-
men had a slightly higher response rate (18.5% vs
10.2% for DTIC alone), overall survival was not
impacted.126 This disappointing result, along with
equally unimpressive results from a large phase 2
cooperative group trial,127 led to the demise of this
regimen.
The combination of cisplatin, vinblastine, and
DTIC (CVD), still used in some settings today, was
published in Cancer as a neoadjuvant (preoperative)
regimen.128 The reported response rate was high;
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48% of patients had either a complete or a partial
response, and the bone marrow suppression was not
as severe as with the Dartmouth regimen. Subse-
quently, CVD was tested in metastatic melanoma.129
This regimen rapidly became a standard approach,
and was subsequently used as the backbone of sev-
eral ‘‘biochemotherapy’’ regimens that included
interleukin (IL)-2 and interferon-a. These regimens
generated tremendous enthusiasm for their very high
response rates (up to or exceeding 50%.).130 Unfortu-
nately, when a randomized Eastern Cooperative On-
cology Group/intergroup trial compared CVD/IL-2/
interferon biochemotherapy to CVD chemotherapy
alone, no significant benefit in overall survival was
seen.131 This lack of overall survival benefit for bio-
chemotherapy over chemotherapy alone has now
been confirmed in a large meta-analysis.132
Given the disappointments with DTIC-based
regimens, many other agents have been tested in
metastatic melanoma patients over the years, with
several of these trials reported in Cancer. Legha et al
reported on the then novel drug paclitaxel in mela-
noma.133 Paclitaxel at a dose of 250 mg/m2 given
over 24 hours produced objective responses in 12%
of previously untreated patients. The nitrosourea
fotemustine, which crosses the blood–brain barrier,
was tested in a French multicenter phase 2 trial. A
response rate of 24.2% was reported, and patients
with brain metastases experienced an impressive
25% objective response rate.134 Subsequently, a major
randomized phase 3 trial compared fotemustine to
DTIC; although fotemustine significantly delayed
brain metastasis and doubled response rates (15.5%
vs 6.8%), overall survival was not significantly
increased (7.3 months vs 5.6 months, P 5 .067).135 A
major limitation of fotemustine, as with other nitro-
soureas, is the high incidence of severe bone marrow
suppression, which could be predicted by a multifac-
torial scoring system.136
High-dose chemotherapy was explored in mela-
noma, as it was in other solid tumor and hematologi-
cal malignancies. In a study published in Cancer,
Thatcher et al reported an extremely high 81%
response rate for a combination of DTIC with mel-
phalan or ifosfamide followed by autologous bone
marrow rescue.137 Unfortunately, a high incidence of
adverse effects, including toxic deaths, was reported
as well. Two further studies in Cancer examined
high-dose cisplatin in combination with DTIC in
melanoma.138,139 Both studies had disappointing
response rates (12% and 17%) and severe toxicity.
High-dose chemotherapy has continued to be tested
intermittently, but overall this approach has not been
successful in melanoma.
A novel method of introducing large molecular
weight chemotherapy agents into cancer cells, poten-
tially overcoming drug resistance mechanisms, is to
use transient electric pulses. Electrochemotherapy
with bleomycin was highly effective in a phase 1/2
trial in causing regression of superficial melanoma
lesions.140 This method of introducing large molecu-
lar weight molecules has been adapted to transfer
DNA and is actively being explored.
The challenge of dealing with the common ter-
minal event in advanced melanoma, central nervous
system metastasis, was laid out by Gottleib, Frei, and
Luce in a 1972 review.141 Recently, the drug temozo-
lomide has shown activity in melanoma.142 This drug
has some advantages over DTIC. It is an orally bio-
available drug that is converted nonenzymatically to
5-(3-methyl-1-triazeno)imidazole-4-carboxamide, the
same active metabolite of DTIC. It also crosses the
blood-brain barrier, which DTIC does not. The com-
bination of temozolomide with thalidomide was
reported to have high levels of activity in a phase 2
single center trial.143 Unfortunately, this was not
corroborated in a cooperative group phase 2 trial,
where this regimen appeared to be only modestly
active in melanoma patients with brain metastases,
but had an unacceptably high incidence of throm-
boembolism,144 a toxicity also reported when thali-
domide was combined with interferon-a.145
IMMUNOLOGIC THERAPIES IN MELANOMA
The field of clinical tumor immunology began over
100 years ago with observations by William Halsted
of a favorable association between lymphocytic infil-
tration of the tumor and the clinical outcome of
breast cancer. The therapeutic use of inflammatory
mediators in the treatment of cancer also began in
the 1890s, with the work of William Coley, a surgeon
who injected large tumors with viable Gram-positive
microorganisms. The resulting inflammatory process
sometimes resulted in tumor regression, but was
associated with significant systemic toxicity and even
mortality. The material, known as Coley toxin, has
come back under discussion in parallel with today’s
more detailed understanding of the cells and mole-
cules involved in the innate and adaptive immune
systems. It was not until much later, in the 1960s
and 1970s, that the foundations of the most success-
ful form of immunotherapy to date, allogeneic bone
marrow transplantation, were established.146 The ca-
nine models that provided the basis for early human
investigation were a rich source of knowledge regard-
ing histocompatibility and the basis of cellular
immunotherapy. Later, it turned out that much of
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the insight into histocompatibility genes and related
genes that control the allo-immune response was
also relevant to the immune response against tumor
antigens, forming the basis for much of contempor-
ary tumor immunotherapy research.
Melanoma has long been a focus of research and
clinical trials of immunotherapy because of its innate
resistance to other therapies as well as the occasional
observation of spontaneous or postinflammatory tu-
mor regression. Many early immunotherapy reports
for melanoma appeared in Cancer. It is possible to
chart the course of the field by reviewing these arti-
cles, which in the tradition of the journal include
both therapeutic trials and clinicopathologic observa-
tions. To review these papers is not only to witness a
glimpse of how the field began, but also to be
reminded of the steady and substantial improve-
ments in study design, statistical analysis, correlative
science, and human subjects protection that have
occurred during the past 6 decades.
Reports began to appear in Cancer in 1973, start-
ing with a large therapeutic trial using autologous tu-
mor coupled to xenogeneic serum gamma globulin,
with the authors reporting activity in 2 patients and
possible immune responses 4 additional patients (a
clinical benefit rate of 12%).147 The first description of
bacillus Calmette–Guerin (BCG) in the adjuvant setting
was the subject of a small trial consisting of 2 different
doses of BCG administered by scarification to patients
with resected high-risk melanoma.148 Although no
conclusions regarding the clinical activity of this ther-
apy could be made on the basis of this 13-patient trial,
the correlative immunologic studies demonstrated
a phenomenon that remains 1 of the recurring themes
in melanoma immunotherapy: the association between
immune responsiveness and favorable outcome.149
Whereas immunotherapy approaches (and clinical
trial design, conduct, and reporting) have evolved to
far more sophisticated levels, the ability to distinguish
response to therapy from general immune responsive-
ness as a predictor of favorable outcome remains a
formidable obstacle. As an example, the recent report
by Gogas et al showed a strong association between
development of autoimmunity during adjuvant inter-
feron-a, and disease-free and overall survival.150 This
provided evidence that we may be able to identify host
protection from melanoma after the therapeutic inter-
vention, but as yet we have not identified predictive
factors for matching patients to therapies, nor have we
developed highly effective treatments that break toler-
ance and overcome the immune resistance and escape
that protect the melanoma from the host.
Attempts to focus on tumor-associated antigens
in melanoma also began in the early 1970s, and the
results from a large series reported from Duke Uni-
versity provided insight into aspects of melanoma
immunology—in particular, the antigenic specificity
of response to vaccination and the impact of expo-
sure to tumor on cytotoxic lymphocyte responses—
that continue to be addressed by today’s research-
ers.151 These investigators also made the observation,
as have others, that patients with visceral metastatic
disease rarely if ever benefited from immunotherapy
and stated that their future trials of vaccine therapy
would be limited to patients with skin and soft tissue
metastasis, ‘‘using chemotherapy in those with more
extensive disease’’ (no wonder chemotherapy got off
to such a poor start).
In a similar approach, the group at Jefferson
reported the use of a mixture of irradiated autologous
melanoma cells plus BCG injected intradermally in
patients with advanced melanoma, observing 4
responses among 18 patients, but noting that res-
ponses were of short duration and occurred only in
those with nonvisceral metastatic sites.152 Although the
same group of investigators had previously reported in
Cancer the regression of a lung metastasis after the
intratumoral injection of multiple cutaneous metasta-
ses with BCG,153 their conclusion in this 1977 article
was that the BCG/autologous tumor vaccine approach
they used did not have general applicability because of
its low overall activity. Although the predominant limi-
tation of BCG therapy for melanoma is indeed its low
activity, the 1975 report in Cancer of deaths from BCG
injections into subcutaneous nodules points out that
even relatively mild immunotherapies can have pro-
found toxicities, an observation that further supports
the crucial need for a thorough understanding of the
mechanisms of action and of toxicity for all of our ther-
apeutic agents or regimens.154
Studies using BCG by various routes continued
throughout the late 1970s and early 1980s,155-158 but
the use of any form of intralesional therapy, including
the purportedly less toxic methanol-extracted residue
of BCG, became less compelling as the data regarding
its low activity and occasionally severe toxicity became
established.159 However, BCG and related preparations
such as DETOX (consisting of mycobacterial cell wall
plus Salmonella phospholipids) continued to be used
in phase 3 trials with allogeneic melanoma vac-
cines.160,161 These vaccines, just as with BCG alone,
have not shown sufficient activity to warrant their rou-
tine use for high-risk melanoma patients.162,163
The later 1970s saw the evolution of other forms
of melanoma vaccination, including the use of oncoly-
sates prepared from surgically excised autologous
melanoma infected with the Newcastle disease virus
or vaccinia virus.164,165 By that time, it had been
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reported that this and other viruses could induce the
production of interferon,166 so the stage was set for
the advent of interferon in melanoma therapy. In Can-
cer in 1983, Retsas et al reported a single response
among 17 pretreated melanoma patients receiving
human lymphoblastoid interferon,167 and the next
year Creagan et al reported a 31-patient trial of high-
dose recombinant interferon-a, given intramuscularly
3 times weekly, with 7 objective responses but sub-
stantial toxicity, predominantly constitutional.168 The
authors’ conclusions that interferon ‘‘has some antitu-
mor activity accompanied by difficult side effects’’
were corroborated by several other reports, including
a larger series by the same group.169,170 They continue
to be valid today; interferon’s use is limited for the
most part to the adjuvant therapy of stage III disease
and to biochemotherapy regimens that contain inter-
feron-a and IL-2 added to combination chemother-
apy, both controversial therapies.171,172 Use of those 2
cytokines without chemotherapy was investigated by
Keilholz et al, who observed promising activity (objec-
tive response rate 41%) with acceptable tolerability
using a regimen of moderate-dose intermittent sub-
cutaneous interferon-a plus a ‘‘decrescendo’’ dose
schedule of intravenous infusional IL-2.173 However,
enthusiasm for this combination was dampened by
subsequent reports that yielded objective response
rates under 10% despite substantial toxicity.174,175
Meanwhile, the more promising data with biochem-
otherapy combinations, detailed in the earlier section
of this review, supported the continued development
of such combinations over double-cytokine regimens.
The investigation, characterization, and thera-
peutic manipulation of tumor antigens in melanoma
has also been well represented by reports appearing
in Cancer over the last 25 years. One of the first and
most comprehensive reports was that of Hollinshead
et al, who performed a series of studies in a multi-
center collaboration.176 In this report, the authors
started by defining tumor-associated antigens from
membrane preparations of primary or metastatic
melanomas that induced delayed-type hypersensitiv-
ity reactions in patients with various stages of dis-
ease. They observed a positive reaction in nearly 90%
of patients with early-stage melanoma who were dis-
ease-free at the time of testing, whereas only 1 of 3
of patients with advanced disease responded. The tu-
mor-associated antigen, identified as a glycolipopro-
tein, was then used as a vaccine in a trial that
featured decreasing doses of antigen in response to
local inflammatory reactions occurring at the starting
doses. These authors went on to describe the use of
DTIC chemotherapy (and in 1 case, an intensive
course of plasmapheresis that induced a second
remission in a patient who had initially responded
and later progressed) to ‘‘reduce circulating inhibi-
tory substances’’ to the vaccine. They reported a low
response rate to chemotherapy and a very high
response rate to ‘‘chemoimmunotherapy’’ (including
a majority of patients who crossed over from the
chemotherapy to the chemoimmunotherapy treat-
ment) as well as the presence of inflammatory infil-
trates in tumors that were biopsied during
regression.176 Further studies to identify tumor-asso-
ciated antigens included efforts of the Memorial-
Sloan Kettering group, which extensively investigated
the immunogenicity of gangliosides found pre-
dominantly on melanoma by using antibodies177 or
ganglioside vaccinations.178 Gene therapy as a com-
ponent of immunotherapy for melanoma has
appeared in the design of vaccines based on mela-
noma cells transduced to express a gene that renders
them immunogenic, such as interferon-g.179
Other current approaches to immunotherapy of
melanoma are reflected in several recent Cancer pub-
lications describing the use of defined-sequence pep-
tide fragments of melanoma antigens with known
histocompatibility antigen restrictions,180 and in
some cases chemical modification of the amino acid
sequence to enhance peptide binding to class I
molecules and/or recognition by the T cell recep-
tor.181 Novel delivery methods have also been
reported, including the intranodal delivery of a plas-
mid encoding an important melanoma tumor anti-
gen.182 Furthermore, 1 of the pioneering reports
describing the use of a fully human antibody against
the CTLA4 molecule that dampens T cell responses
and appears to mediate some of the activity of regu-
latory T cells appeared in Cancer in 2006.183
Adoptive immunotherapy, the prototype of which
is allogeneic hematopoietic cell transplant for hema-
tologic malignancy, has been applied to melanoma
and other solid tumors since the 1980s. Whereas
allogeneic transplants have rarely provided sufficient
activity to be worthy of further pursuit,184,185 manip-
ulations of autologous cell products may provide a
level of antitumor cytotoxicity not achieved with any
of the other immunotherapy strategies detailed
above.186-190 Ironically, as investigators came to
believe that high-dose IL-2 appeared to provide most
or all of the therapeutic activity attributed to IL-2
plus lymphokine-activated killer cells, the addition of
cells was largely abandoned.191-193
Conclusions
In the 60 years of existence of Cancer, great strides in
understanding and treatment of melanoma have
been made. Although treating advanced disease has
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remains challenging, the road to further advances
has already begun to be mapped with discoveries in
the genetic heterogeneity of melanoma, knowledge
of pathways that can be targeted, and a growing
understanding of the tumor microenvironment and
the host’s immunological responses. We look forward
to Cancer’s continuing contributions to our knowl-
edge of melanoma.
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